News

A compound that blocks the activity of so-called HDAC enzymes in the brain improved learning in mouse models of Alzheimer’s disease, according to data that Regenacy Pharmaceuticals presented at the recent 2017 Alzheimer’s Association International Conference (AAIC) July 16-20 in London. Regenacy’s RCY-1305 blocks the enzymes HDAC1 and HDAC2, which…

The Gerontological Society of America has developed a free online toolkit to help primary-care doctors detect and diagnose cognitive impairment, dementia and Alzheimer’s disease, the most common type of dementia. The toolkit is based on a four-step process for detecting cognitive impairment and diagnosing dementia earlier. The society named…

The Alzheimer’s Research and Prevention Foundation (ARPF) will launch a new Brain Longevity Therapy Training Program to educate wellness and healthcare workers on the four pillars of Alzheimer’s disease prevention: diet, stress management, exercise and spiritual fitness. The spiritual fitness segment focuses on yoga and meditation techniques,…

A plan to test a multi-dimensional, lifestyle-based approach to preventing cognitive decline and dementia in people at risk of Alzheimer’s was one of the important revelations that surfaced at the 2017 Alzheimer’s Association International Conference, experts said. Other convention highlights that the Alzheimer’s Association identified included: Interim results of a…

Researchers developed a new method for capturing proteins implicated in several diseases, including Alzheimer’s. The technique promises to accelerate the identification of altered proteins underlying disease progression (biomarkers). This knowledge may later translate into new targeted therapeutics. The study, “A mutant O-GlcNAcase enriches Drosophila developmental regulators,” was published in the…

Alzheimer’s research is gaining momentum, with 27 Phase 3 and eight Phase 2 clinical trials either in progress or expected over the next five years. The good news surfaced in a revised pipeline analysis of Alzheimer’s therapies that researchers presented at the Alzheimer’s Association International Conference in London. The event, which started…

Axsome Therapeutics has announced that the first patient was enrolled in the ADVANCE-1 Phase 2/3 trial evaluating the effectiveness and safety of its investigative therapy AXS-05 for the treatment of agitation in Alzheimer’s disease patients. Agitation is related to anxiety and is reported by nearly 50 percent of Alzheimer’s patients. It’s…

A poor night’s sleep may increase the levels of proteins associated with Alzheimer’s disease, say researchers, noting that their findings may be especially important for people with chronic sleep disorders. The study by scientists at Stanford University, Washington University School of Medicine in St. Louis and Radboud University Medical Centre in…

Expression of the protein ANK1 (ankyrin repeat domain-containing protein) is four fold higher in the microglia of patients with Alzheimer’s disease (AD). Microglia are a type of immune cell found in the brain and key regulators of the inflammatory cascade typified in early Alzheimer’s development. ANK1 previously has been identified as…

E-Scape Bio, the Gladstone Institutes’ spin-off company working to develop therapies for neurodegenerative disorders such as Alzheimer’s disease, announced that it has raised a total of $63 million in Series A financing from investors. The biotech startup is developing small-molecule drugs that target apoE4, a gene thought to increase the risk…